Maung, SW,Leahy, M,O'Leary, HM,Khan, I,Cahill, MR,Gilligan, O,Murphy, P,McPherson, S,Jackson, F,Ryan, M,Hennessy, B,McHugh, J,Goodyer, M,Bacon, L,O'Gorman, P,Nee, A,O'Dwyer, M,Enright, H,Saunders, J,O'Keeffe, D

2013

January

British Journal Of Haematology

A multi-centre retrospective study of rituximab use in the treatment of relapsed or resistant warm autoimmune haemolytic anaemia

Published

()

multicentre safety rituximab autoimmune haemolytic anaemia retrospective ADULT PATIENTS THERAPY EFFICACY SPLENECTOMY SAFETY

163

118

122

This retrospective analysis assessed the response, safety and duration of response to standard dose rituximab 375 mg/m(2) weekly for four weeks as therapy for patients with primary or secondary warm autoimmune haemolytic anaemia (WAIHA), who had failed initial treatment. Thirty-four patients received rituximab for WAIHA in seven centres in the Republic of Ireland. The overall response rate was 70 center dot 6% (24/34) with 26 center dot 5% (9/34) achieving a complete response (CR). The time to response was 1 month post-initiation of rituximab in 87 center dot 5% (21/24) and 3 months in 12 center dot 5% (3/24) of patients. The median duration of follow-up was 36 months (range 6-90 months). Of the patients who responded, 50% (12/24) relapsed during follow up with a median time to next treatment of 16 center dot 5 months (range 6-60 months). Three patients were re-treated with rituximab 375 mg/m2 weekly for four weeks at relapse and responded. There was a single episode of neutropenic sepsis. Rituximab is an effective and safe treatment for WAIHA but a significant number of patients will relapse in the first two years post treatment. Re-treatment was effective in a small number of patients, suggesting that intermittent pulse treatment or maintenance treatment may improve long-term response.

10.1111/bjh.12486